182
Views
4
CrossRef citations to date
0
Altmetric
Letters

Safe and effective tumour necrosis factor-α inhibitor (etanercept) treatment of chronic episodic arthritis in a patient with cystic fibrosis

, , &
Pages 330-331 | Accepted 17 Nov 2015, Published online: 20 Jan 2016

References

  • Botton E, Saraux A, Laselve H, Jousse S, Le Goff P. Musculoskeletal manifestations in cystic fibrosis. Joint Bone Spine 2003;70:327–35.
  • Gibson DJ, Gallagher CG, Doherty GA. Infliximab is safe and induces sustained remission with complete mucosal healing in Crohn’s disease in a patient with pan resistant pseudomonas cystic fibrosis: a case report. J Crohns Colitis 2014;8:1561–2.
  • Vincenzi F, Bizzarri B, Ghiselli A, De’ Angelis N, Fornaroli F, De’ Angelis GL. Cystic fibrosis and Crohn’s disease: successful treatment and long term remission with infliximab. World J Gastroenterol 2010;16:1924–7.
  • Casserly B, Donat W. Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha. Lung 2009;187:149–52.
  • Visser S, Martin M, Serisier DJ. Improvements in cystic fibrosis lung disease and airway inflammation associated with etanercept therapy for rheumatoid arthritis: a case report. Lung 2012;190:579–81.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.